

1635- IPW  
muge

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: ATKINS  
Attkins  
Filed: September 9, 2002  
Appln. No.: 09/889,075  
For: CATALYTIC MOLECULES

Atty. Docket: ATKINS1  
Conf. No.: 6813  
Art Unit:  
Examiner:  
Washington, D.C.  
February 7, 2005

**INFORMATION DISCLOSURE STATEMENT [IDS]**

Honorable Commissioner for Patents  
U.S. Patent and Trademark Office  
Customer Service Window  
Randolph Building, Mail Stop Amendment  
401 Dulany Street  
Alexandria, VA 22314  
Sir:

This Information Disclosure Statement is submitted in accordance with 37 CFR §§1.97, 1.98, and it is requested that the information set forth in this statement and in the listed documents be considered during the pendency of the above-identified application, and any other application relying on the filing date of the above-identified application or cross-referencing it as a related application.

[X] 1. This IDS should be considered, in accordance with 37 CFR §1.97, as it is filed:

[X] B. before the mailing date of a first office action on the merits or before the mailing of a first Office action after the filing of a Request for Continued Examination under 37 CFR §1.114

[X] 2. In accordance with 37 CFR §1.98, this IDS includes a list (e.g., form BN/SB/08A/B) of all patents, publications, or other information submitted for consideration by the office, either incorporated into this IDS or as an attachment hereto. Other than U.S. patent(s) and/or published U.S. application(s), which 37 CFR §1.98(a)(2)(ii) does not require to be filed unless specifically required by the Office, a copy of each document listed is attached.

[X] 3. Document(s) AB is/are not in the English language.  
In accordance with 37 CFR §1.98(a)(3), Applicant states:

[X] An English translation of each document AB (or of the pertinent portions thereof), or a copy of an English-language abstract (or claim) is enclosed.

[X] A concise explanation of the relevance of document(s) AB is found in the attached Supplementary Partial European search report (see reply to Comment 68 in the preamble to the final rules; 1135 OG 13 at 20).

[X] 4. No explanation of relevance is necessary for documents in the English language (see reply to Comments 67 and 68 in the preamble to the final rules; 1135 OG 13 at 20).

[X] 5. Other information being provided for the examiner's consideration follows:

*Supplementary Partial European Search Report*

6. In accordance with 37 CFR §§1.97(g) and (h), the filing of this IDS should not be construed as a representation that a search has been made or that information cited is, or is considered to be, material to patentability as defined in 37 CFR §1.56(b), or that any cited document listed or attached is (or constitutes) prior art. Unless otherwise indicated, the date of publication indicated for an item is taken from the face of the item and Applicant reserves the right to prove that the date of publication is in fact different.


Respectfully submitted,

BROWDY AND NEIMARK  
Attorneys for Applicant(s)

By: 

Anne M. Kornbau  
Registration No. 25,884

AMK:ses  
624 Ninth Street, N.W., Suite 300  
Washington, D.C. 20001-5303  
Telephone: (202) 628-5197  
Facsimile: (202) 737-3528  
G:\BN\B\Blaj\atkins1\pto\ids.fee.doc



Substitute for form 1449A/1-01

## Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 1

Application Number	09/889,075
Filing Date	September 9, 2002
First Named Inventor	ATKINS
Group Art Unit	
Examiner Name	
Attorney Docket Number	ATKINS1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2,3</sup> (known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Number Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>

**OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
	AA	PEREZ-CASTILLO A et al "NGFI-A Gene Expression is Necessary for T Lymphocyte Proliferation" Journal of Biological Chemistry, American Society of Biological Chemists, Baltimore, MD, US. Vol 268, No. 26, (September 15, 1993) pp: 19445-19450	
	AB	RUPPRECHT H D et al "Der Transkriptionsfaktor EGR-1 Reguliert Das Wachstum Glomerulaerer Mesangiumzellen The Transcriptional Regulator EGR-1 and Growth Control of GL Omerula Mesangial Cells" Medizinische Klinik, Vol 92, No. 2 (1997) pp:68-73	
	AC	SACHINIDIS AGAPIOS et al "Oligodeoxynucleotides directed to early growth response gene-1 mRNA inhibit DNA synthesis in the smooth muscle cell" European Journal of Pharmacology, Vol. 309, No.1 (1996) pp: 95-105	
	AD	DATABASE EMBL 'Online! (July 6, 1989) "Rattus norvegicus nerve growth factor (NGF-IA) gene, complete cds" XP002303013 retrieved from EBI accession no. EM_PRO:RNNGF1A Database accession no. J04154	

Examiner  
SignatureDate  
Considered

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.